Kirkland-based health technology company Freespira has raised $22.6 million, according to a Monday filing with the Securities and Exchange Commission.
The money came in the form of equity funding, according to the filing. Freespira raised $10 million in 2020 in a round led by Lightspeed Venture Partners, which has invested in big names like Snap and Stripe.
The company didn't immediately respond to a request for more information.
Freespira, which makes technology aimed at treating panic attacks and panic disorder, was founded in 2013, according to the company's LinkedIn page. The company makes a sensor, nasal cannula and tablet designed to help patients regulate respiration and exhaled carbon dioxide levels. Freespira says on its website hypersensitivty to carbon dioxide is often linked with panic and post-traumatic stress disorder symptoms.
Related coverage:
Users do two 17-minute sessions a day for 28 days and return the equipment at the end. A coach does training and weekly check-ins with users as well. Its equipment is cleared by the Food and Drug Administration.
In June 2022, Freespira named Joseph Perekupka as CEO. Perekupka had spent almost two years at the company from 2019 to 2021 as well, but he left the company for roughly a year to work for a life sciences consulting company before coming back to take the CEO role. Perekupka spent more than four years at BrainsWay, a Burlington, Massachusetts-based company that makes devices to treat mental health disorders, before his first stint with Freespira.
The SEC filing lists Stephen Bruso as a director at Freespira. Bruso is a venture capitalist with Morningside, a 38-year-old firm that has invested in the health monitoring company Casana and in Eko Devices, a medical screening company.
